Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017

Ding Ding, Ammar A. Javed, Dea Cunningham, Jonathan Teinor, Michael Wright, Zunaira N. Javed, Cara Wilt, Lindsay Parish, Mary Hodgin, Amy Ryan, Carol Judkins, Keith McIntyre, Rachel Klein, Nilo Azad, Valerie Lee, Ross Donehower, Ana De Jesus-Acosta, Adrian Murphy, Dung T. Le, Eun Ji ShinAnne Marie Lennon, Mouen Khashab, Vikesh Singh, Alison P. Klein, Nicholas J. Roberts, Amy Hacker-Prietz, Lindsey Manos, Christi Walsh, Lara Groshek, Caitlin Brown, Chunhui Yuan, Alex B. Blair, Vincent Groot, Georgios Gemenetzis, Jun Yu, Matthew J. Weiss, Richard A. Burkhart, William R. Burns, Jin He, John L. Cameron, Amol Narang, Atif Zaheer, Elliot K. Fishman, Elizabeth D. Thompson, Robert Anders, Ralph H. Hruban, Elizabeth Jaffee, Christopher L. Wolfgang, Lei Zheng, Daniel A. Laheru

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Recent research on genomic profiling of pancreatic ductal adenocarcinoma (PDAC) has identified many potentially actionable alterations. However, the feasibility of using genomic profiling to guide routine clinical decision making for PDAC patients remains unclear. We retrospectively reviewed PDAC patients between October 2013 and December 2017, who underwent treatment at the Johns Hopkins Hospital and had clinical tumor next-generation sequencing (NGS) through commercial resources. Ninety-two patients with 93 tumors tested were included. Forty-eight (52%) patients had potentially curative surgeries. The median time from the tissue available to the NGS testing ordered was 229 days (interquartile range 62–415). A total of three (3%) patients had matched targeted therapies based on genomic profiling results. Genomic profiling guided personalized treatment for PDAC patients is feasible, but the percentage of patients who receive targeted therapy is low. The main challenges are ordering NGS testing early in the clinical course of the disease and the limited evidence of using a targeted approach in these patients. A real-time department level genomic testing ordering system in combination with an evidence-based flagging system for potentially actionable alterations could help address these shortcomings.

Original languageEnglish (US)
Pages (from-to)221-228
Number of pages8
JournalCancer Letters
Volume497
DOIs
StatePublished - Jan 28 2021

Keywords

  • Actionable alteration
  • Clinical genomic testing
  • Matched therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017'. Together they form a unique fingerprint.

Cite this